or Try an Advanced Search...

    Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 13.18 -11.37% -1.69
    YMAB closed down 11.37 percent on Tuesday, November 12, 2024, on 1.22 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical YMAB trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 200 DMA Bearish 0.00%
    Fell Below 50 DMA Bearish 0.00%
    MACD Bearish Signal Line Cross Bearish 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Earnings Movers Other 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Gapped Down Weakness 0.00%
    Older End-of-Day Signals for YMAB ...

       Recent Intraday Alerts

    Alert Time
    Fell Below 200 DMA about 12 hours ago
    Gap Down Closed about 14 hours ago
    60 Minute Opening Range Breakdown about 14 hours ago
    20 DMA Resistance about 14 hours ago
    Down 5% about 14 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    YMAB Chart by TradingView
    Basic chart:

    Profile

    Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Cancer Treatment Therapeutic Products Blastoma Brain Tumor Cancer Center Glioma Metastases Neuroblastoma Diffuse Intrinsic Pontine Glioma Kettering Cancer Center Memorial Sloan Refractory

    Is YMAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 9 Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
    Nov 8 Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript
    Nov 8 Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
    Nov 8 Y-mAbs Therapeutics GAAP EPS of -$0.16 beats by $0.01, revenue of $18.46M misses by $4.8M
    Nov 8 Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
    Nov 5 Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
    Nov 4 Y-mAbs and Nobelpharma sign license and distribution agreement for DANYELZA in Japan
    Nov 4 Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
    Nov 1 Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
    Oct 25 Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
    See more YMAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 20.9
    52 Week Low 5.04
    Average Volume 224,036
    200-Day Moving Average 13.83
    50-Day Moving Average 14.10
    20-Day Moving Average 14.76
    10-Day Moving Average 14.88
    Average True Range 0.93
    RSI (14) 36.31
    ADX 22.41
    +DI 13.23
    -DI 38.22
    Chandelier Exit (Long, 3 ATRs) 13.31
    Chandelier Exit (Short, 3 ATRs) 15.26
    Upper Bollinger Bands 15.79
    Lower Bollinger Band 13.73
    Percent B (%b) -0.27
    BandWidth 13.93
    MACD Line 0.17
    MACD Signal Line 0.30
    MACD Histogram -0.1285
    Fundamentals Value
    Market Cap 574.93 Million
    Num Shares 43.6 Million
    EPS -0.45
    Price-to-Earnings (P/E) Ratio -29.29
    Price-to-Sales 6.16
    Price-to-Book 5.71
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.76
    Resistance 3 (R3) 16.04 15.46 15.33
    Resistance 2 (R2) 15.46 14.80 15.32 15.19
    Resistance 1 (R1) 14.32 14.40 14.03 14.04 15.04
    Pivot Point 13.74 13.74 13.60 13.60 13.74
    Support 1 (S1) 12.60 13.08 12.31 12.32 11.32
    Support 2 (S2) 12.02 12.68 11.88 11.17
    Support 3 (S3) 10.88 12.02 11.03
    Support 4 (S4) 10.60